| The influence of hepatitis C virus genetic region on phylogenetic clustering analysis FMJ Lamoury, B Jacka, S Bartlett, RA Bull, A Wong, J Amin, J Schinkel, ... PloS one 10 (7), e0131437, 2015 | 46 | 2015 |
| Sequencing of hepatitis C virus for detection of resistance to direct‐acting antiviral therapy: A systematic review SR Bartlett, J Grebely, AA Eltahla, JD Reeves, AYM Howe, V Miller, ... Hepatology communications 1 (5), 379-390, 2017 | 36 | 2017 |
| Demonstration of near-elimination of hepatitis C virus among a prison population: the Lotus Glen Correctional Centre hepatitis C treatment project SR Bartlett, P Fox, H Cabatingan, A Jaros, C Gorton, R Lewis, E Priscott, ... Clinical Infectious Diseases 67 (3), 460-463, 2018 | 31 | 2018 |
| A molecular transmission network of recent hepatitis C infection in people with and without HIV: Implications for targeted treatment strategies SR Bartlett, JO Wertheim, RA Bull, GV Matthews, FMJ Lamoury, ... Journal of viral hepatitis 24 (5), 404-411, 2017 | 22 | 2017 |
| Moving towards hepatitis C microelimination among people living with human immunodeficiency virus in Australia: The CEASE Study M Martinello, J Yee, SR Bartlett, P Read, D Baker, JJ Post, R Finlayson, ... Clinical Infectious Diseases 71 (6), 1502-1510, 2020 | 10* | 2020 |
| HIV infection and hepatitis C virus genotype 1a are associated with phylogenetic clustering among people with recently acquired hepatitis C virus infection SR Bartlett, B Jacka, RA Bull, F Luciani, GV Matthews, FMJ Lamoury, ... Infection, Genetics and Evolution 37, 252-258, 2016 | 8 | 2016 |
| The population level care cascade for hepatitis C in British Columbia, Canada as of 2018: Impact of direct acting antivirals SR Bartlett, A Yu, N Chapinal, C Rossi, Z Butt, S Wong, M Darvishian, ... Liver International 39 (12), 2261-2272, 2019 | 7 | 2019 |
| Sustained virological response from interferon-based hepatitis C regimens is associated with reduced risk of extrahepatic manifestations C Rossi, D Jeong, S Wong, G McKee, ZA Butt, J Buxton, J Wong, ... Journal of hepatology 71 (6), 1116-1125, 2019 | 7 | 2019 |
| Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre‐and post‐universal access to direct‐acting antiviral treatment in … S Bajis, J Grebely, B Hajarizadeh, T Applegate, AD Marshall, ... Journal of Viral Hepatitis 27 (3), 281-293, 2020 | 6 | 2020 |
| Loss to follow‐up: a significant barrier in the treatment cascade with direct‐acting therapies M Darvishian, S Wong, M Binka, A Yu, A Ramji, EM Yoshida, J Wong, ... Journal of Viral Hepatitis 27 (3), 243-260, 2020 | 5 | 2020 |
| A latent class approach to identify multi‐risk profiles associated with phylogenetic clustering of recent hepatitis C virus infection in Australia and New Zealand from 2004 to 2015 SR Bartlett, TL Applegate, BP Jacka, M Martinello, FMJ Lamoury, M Danta, ... Journal of the International AIDS Society 22 (2), e25222, 2019 | 4 | 2019 |
| Universal access to DAA therapy paves the way for HCV control and elimination among people living with HIV in Australia M Martinello, S Bartlett, G Dore, R Bopage, R Finlayson, D Baker, M Bloch, ... Journal of Hepatology 68, S312-S313, 2018 | 4 | 2018 |
| Addressing the syndemic of HIV, hepatitis C, overdose, and COVID-19 among people who use drugs: The potential roles for decriminalization and safe supply M Bonn, A Palayew, S Bartlett, TD Brothers, N Touesnard, M Tyndall Journal of studies on alcohol and drugs 81 (5), 556-560, 2020 | 3 | 2020 |
| Interferon λ 3 and 4 genotyping using high-resolution melt curve analysis suitable for multiple clinical sample types FMJ Lamoury, S Bartlett, B Jacka, B Hajarizadeh, J Grebely, GV Matthews, ... The Journal of molecular diagnostics 17 (5), 583-589, 2015 | 3 | 2015 |
| Identification of critical residues in the bifunctional phosphoenolpyruvate synthetase kinase/phosphotransferase of Escherichia coli S Bartlett, J Seeliger, JN Burnell Current Topics in Biochemical Research 14, 77-83, 2012 | 3 | 2012 |
| Real-world effectiveness of sofosbuvir/velpatasvir for treatment of chronic hepatitis C in British Columbia, Canada: A population-based cohort study J Wilton, S Wong, A Yu, A Ramji, D Cook, ZA Butt, M Alvarez, M Binka, ... Open forum infectious diseases 7 (3), ofaa055, 2020 | 2 | 2020 |
| REAL-WORLD EFFECTIVENESS OF SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR AS A HEPATITIS C VIRUS INFECTION SALVAGE TREATMENT M Krajden, D Cook, S Wong, J Wilton, ZA Butt, S Bartlett, M Pearce, ... HEPATOLOGY 70, 914A-914A, 2019 | 2 | 2019 |
| SAT-235-Low HCV reinfection incidence following DAA treatment scale-up in people living with HIV in Australia SH Hooshyar, M Martinello, J Yee, S Bartlett, P Read, D Baker, J Post, ... Journal of Hepatology 70 (1), e734, 2019 | 1 | 2019 |
| Drug-related deaths in a population-level cohort of people living with and without hepatitis C virus in British Columbia, Canada H Samji, A Yu, S Wong, J Wilton, M Binka, M Alvarez, S Bartlett, M Pearce, ... International Journal of Drug Policy 86, 102989, 2020 | | 2020 |
| Syndemic profiles of people living with hepatitis C virus using population-level latent class analysis to optimize health services E Clementi, S Bartlett, M Otterstatter, JA Buxton, S Wong, A Yu, ZA Butt, ... International Journal of Infectious Diseases 100, 27-33, 2020 | | 2020 |
Gail MatthewsKirby Institute, University of New South WalesVerified email at kirby.unsw.edu.au
